A successful outcome to the Phase II pilot trial will also meet one of the key requirements to progress discussions with Novartis Animal Health/Elanco regarding the Option Agreement.
$2.6m cash at hand and Debt Free with no loans or liabilities.
BRI will flavour the product and increase efficacy.
Ann: Appendix 4C - Quarterly Report & Brief Company Update, page-4
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
17.5¢ |
Change
0.005(2.94%) |
Mkt cap ! $82.69M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 17.5¢ | 17.0¢ | $41.28K | 236.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 12 | 567354 | 17.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 17.5¢ | 63944 | 6 |
View Market Depth
| Last trade - 14.22pm 10/09/2024 (20 minute delay) ? |
| PAA (ASX) Chart |